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Background. Oral fluid-based rapid tests are promising for improving HIV diagnosis and screening. However, recent reports
from the United States of false-positive results with the oral OraQuickH ADVANCE HIV1/2 test have raised concerns about their
performance in routine practice. We report a field evaluation of the diagnostic accuracy, client preference, and feasibility for
the oral fluid-based OraQuickH Rapid HIV1/2 test in a rural hospital in India. Methodology/Principal Findings.. A cross-
sectional, hospital-based study was conducted in 450 consenting participants with suspected HIV infection in rural India. The
objectives were to evaluate performance, client preference and feasibility of the OraQuickH Rapid HIV-1/2 tests. Two OraquickH
Rapid HIV1/2 tests (oral fluid and finger stick) were administered in parallel with confirmatory ELISA/Western Blot (reference
standard). Pre- and post-test counseling and face to face interviews were conducted to determine client preference. Of the 450
participants, 146 were deemed to be HIV sero-positive using the reference standard (seropositivity rate of 32% (95%
confidence interval [CI] 28%, 37%)). The OraQuick test on oral fluid specimens had better performance with a sensitivity of
100% (95% CI 98, 100) and a specificity of 100% (95% CI 99, 100), as compared to the OraQuick test on finger stick specimens
with a sensitivity of 100% (95% CI 98, 100), and a specificity of 99.7% (95% CI 98.4, 99.9). The OraQuick oral fluid-based test was
preferred by 87% of the participants for first time testing and 60% of the participants for repeat testing. Conclusion/
Significance. In a rural Indian hospital setting, the OraQuickH Rapid- HIV1/2 test was found to be highly accurate. The oral
fluid-based test performed marginally better than the finger stick test. The oral OraQuick test was highly preferred by
participants. In the context of global efforts to scale-up HIV testing, our data suggest that oral fluid-based rapid HIV testing
may work well in rural, resource-limited settings.
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INTRODUCTION
Rapid point-of-care HIV testing is a very important component of
HIV control initiatives and programs. In particular, non-invasive,
simple, accurate oral fluid-based rapid tests have the potential to
make a big impact on HIV screening programs, especially in areas
where laboratory infrastructure is poor or unavailable. Oral fluid-
based testing also opens the possibility of home-based HIV testing.
The OraQuick ADVANCEH HIV1/2 test (OraSure Technologies
Inc, Philadelphia, USA) is the first and only rapid test to be
approved by the US Food and Drug Administration (FDA) for use
in oral fluid, finger stick, whole blood and plasma specimens.
While several studies have shown this test to be accurate in many
settings,[1,2] in December 2005, unusually high rates of false-
positive results with the oral fluid-based OraQuickH ADVANCE
HIV1/2 test were reported in select cities in the United States.
(notably, San Francisco and New York City).[3,4] This raised
concerns about the overall performance of oral fluid testing in
general, and led to speculations that oral fluid tests perform worse
than blood-based rapid HIV tests.
In the case of San Francisco and New York city, it was initially
unclear whether factors such as lot variation, product shelf life,
collection techniques, storage temperature, and site conditions
affected the accuracy of the oral OraQuick test.[4] Following these
reports, the US Centers for Diseases Control and Prevention
(CDC) recommended a parallel testing strategy with the use of two
OraQuick tests, followed by confirmation of test results with
a reference standard.[5] Recently, the CDC conducted an
investigation into the cluster of false-positive test results with oral
fluid OraQuick test in Minnesota [6]. This investigation failed to
identify a cause for the increase in false-positive test results from an
isolated cluster.[6] Thus, there is some lingering skepticism
regarding the field performance of the oral fluid-based HIV test.
In this context, there is a need for real world field studies to
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PLoS ONE | www.plosone.org 1 April 2007 | Issue 4 | e367evaluate the accuracy and performance characteristics of oral
fluid-based rapid HIV testing, especially in resource limited
settings where they can contribute the most. We evaluated the
diagnostic accuracy of the OraQuick rapid HIV 1/2 test in
a hospital setting in rural India.
India has the second largest number of HIV infected people in
the world, second only to South Africa.[7] However, it has been
reported that HIV prevalence in southern Indian States is on the
decline [8] Knowledge of sero-status is the cornerstone of HIV
prevention, diagnosis and linkages to care and prevention. Many
Indians including rural poor, are unaware of their sero-status. [9]
Rapid point-of-care HIV tests can greatly aidin knowing sero-status
by providing faster and accurate results in minutes. In India, rapid
HIV tests currently marketed are blood based tests that are
cumbersome, require trained laboratory technicians, and test results
are often not available at the point-of-care. Moreover, in rural areas
resources are limited, laboratory technicians frequently unavailable,
phlebotomy is difficult and culturally less preferred. Therefore,
follow up on HIV test results can prove to be very challenging. In
such settings, oral fluid-based rapid tests provide a convenient and
feasible alternative to blood-based testing.[2] Although oral fluid-
based rapid testing has several attractive features, few studies have
evaluatedthelatestversionsoftheOraQuickRapidHIV1/2testsin
rural India. We report the results of a cross-sectional hospital-based
study conducted in Maharashtra state in India.
Our study objectives were: 1) to determine the diagnostic
accuracy of the OraQuick Rapid HIV-1/2 tests (performed
independently on both oral mucosal transudate (OMT) and finger
stick blood specimens) in a parallel testing strategy, 2) to determine
client preference for oral fluid-based testing in a rural hospital
setting, and 3) to evaluate feasibility of conducting oral fluid tests in
a rural resource constrained setting.
MATERIALS AND METHODS
Study setting
Our study was conducted at the Mahatma Gandhi Institute of
Medical Sciences (MGIMS), a rural teaching hospital in
Sevagram, Central India. This busy 650-bed tertiary hospital
has over 350,000 patient visits each year. Our study was
Figure 1. HIV Testing Algorithm
doi:10.1371/journal.pone.0000367.g001
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community-based HIV prevalence data exist for Sevagram. The
study was approved by ethics committees at the University of
California, Berkeley, and the Mahatma Gandhi Institute of
Medical Sciences, Sevagram, India. A written informed consent
was obtained from all participants, and all HIV tests were done
after appropriate counseling.
Study participants: inclusion and exclusion criteria
Participants for this study were recruited from both inpatient and
outpatient facilities of the departments of internal medicine, and
dermatology (which also provides care for patients with sexually
transmitted infections). A convenience-based sampling method
was employed for recruiting participants. Consenting participants
were interviewed and provided pre-test and post-test counseling as
per the guidelines of the National AIDS Control Organization
(NACO), India.
Participants were administered index and reference standard
tests concurrently. Data on demographic characteristics and client
preference for various HIV testing modalities was also collected,
along with data on risk factors for HIV.
Participants were eligible if any of the following criteria were
met: a) an adult (.18 years of age); and b) presence of signs and/
or symptoms of HIV infection (i.e., unexplained weight loss for
more than 6 months; unexplained fever for more than 3 months;
chronic cough or weight loss for more than 3 months; loose stools
for more than 1 month; generalized lymphadenopathy of non
malignant origin); c) or, presence of signs and symptoms of
opportunistic infections (i.e., pulmonary or extrapulmonary
tuberculosis, candidiasis, Pneumocystis jiroveci pneumonia, aseptic
meningitis, toxoplasmosis, primary central nervous system lym-
phoma, diarrhea, or Kaposi’s sarcoma); d) or, presence of one or
more risk factors for HIV infection, (i.e., concurrent sexually
transmitted infection, spouse of a known HIV-positive individual,
recent unprotected intercourse with a commercial sex worker,
intravenous drug user, recipient of multiple unscreened blood
products). Participants were excluded if they were: a) pregnant or
breast feeding; or b) had chronic debilitating conditions or mental
health disorders that would preclude informed consent.
HIV test methods and lab procedures
After appropriate pre-test counseling by a trained health worker,
all eligible and consenting participants received the following
index tests (OraQuick rapid tests performed on oral-fluid as well as
finger stick blood specimens) and the reference standard. The
reference standard (Table 1) was based on the CDC guidelines for
rapid testing. The reference standard used for confirmation of
preliminary positives was a combination of repeat enzyme-linked
immunoassay (ELISA) and Western Blot. For confirmation of
preliminary negatives, one ELISA test alone was used as the
reference standard.
Flowchart 1 illustrates the overall testing protocol and algorithm
employed. The OraQuickH rapid HIV1/2 tests were applied
independently and in parallel, to oral mucosal fluid specimens and
to finger stick blood specimens, according to the manufacturer’s
instructions. Standard criteria recommended by the manufacturer
(OraSure Technologies, Inc, PA, USA) were used to classify the
results as ‘‘negative,’’ ‘‘reactive,’’ or ‘‘invalid.’’ For confirmatory
testing, venipuncture was performed on participants, and blood
samples were collected for ELISA [VironostikaH HIV Uniform II
Ag/Ab Plus O; Organon Teknika Corp, NC, USA] and Western
Blot tests (Qualicode HIV1/2 Kit; Immunetics technologies,
Boston, USA].
Testing was conducted in a double-blind manner. Each test
negative participant received two Oraquick tests and one ELISA
test. Each test positive participant received two Oraquick tests, two
ELISA tests, one internal Western Blot and one external Western
Blot (Table 1). The external Western Blot test was conducted by
an external reference laboratory, as part of quality assurance. The
trained health worker who performed OraQuick tests was
unaware of the reference standard results. The laboratory
technician performing the ELISA and Western Blot assays was
blinded to the results of the OraQuick rapid tests. However, both
OraQuick tests (oral fluid and finger stick) were performed by the
same health worker at the same time, and thus not blinded. After
HIV testing, test results were communicated to the patient by
a trained health worker. Post-test counseling was conducted per
NACO guidelines. [9]
Questionnaires were administered in face to face interviews by
trained health workers. After pre-test counseling session, in-
formation on demographics, risk factors was obtained from
participants. After post-test counseling, information on past and
current HIV test experience and preference for current test
methods was obtained and recorded. [9]
Statistical Analysis Analysis was conducted using Stata
software (version 9.0; Stata Corp, College Station, TX, USA).
The main outcomes were diagnostic accuracy measures, estimated
using sensitivity, specificity, and predictive values, along with 95%
confidence intervals (CI). Concordance between test results were
estimated using kappa statistic.
RESULTS
Description of the study population
A total of 450 participants were recruited and tested for HIV. The
median age of the study participants was 34 years (range 18–
88 years). Of the 450 participants, 74% were men. Most patients
Table 1. Testing algorithm and reference standard
..................................................................................................................................................
Scenario
OraQuick
oral fluid
OraQuick
finger stick ELISA#1 ELISA#2 Western Blot* Tests performed
1 NEG NEG then NEG then STOP Not done Not done Testing stopped with one EIA
2 NEG NEG then POS NEG Done All tests performed
3 POS POS then POS POS Done All tests performed
4 POS NEG then POS NEG Done All tests performed
5 NEG POS then POS POS Done All tests performed
*If Western Blot was indeterminate, ELISA (enzyme-linked immuno-assay) was repeated on stored sera; if repeatedly indeterminate, the sequence was repeated with
a fresh blood sample
*Ref: CDC guidelines for rapid testing
doi:10.1371/journal.pone.0000367.t001
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PLoS ONE | www.plosone.org 3 April 2007 | Issue 4 | e367(65%) were rural laborers and farmers. About 39% of participants
presented with signs and symptoms suggestive of HIV infection;
44% had signs and symptoms suggestive of opportunistic or AIDS
defining illnesses, and 17% had one or more risk factors for HIV
infection. About 9% of the participants had been tested for HIV
infection in the past.
Prevalence of HIV infection using reference
standard
Of the 450 participants, 146 were deemed HIV positive using the
reference standard of ELISA and Western Blot, yielding
a prevalence of 32% (95% CI 28%, 37%). In all cases, ELISA
and Western Blot results were 100% concordant.
Diagnostic accuracy of OraQuick tests
All 450 participants underwent both OraQuick and ELISA/
Western Blot tests. Acceptability of the test refers to the proportion
of people who agreed to get tested voluntarily of the eligible
persons who were offered testing. In our study, the test
acceptability was 100% (450/450). For all patients, OraQuick
results were obtained between 20–40 minutes, while ELISA and
Western Blot results were available within 2 weeks of phlebotomy.
No OraQuick test result was reported as indeterminate or invalid.
As shown in Table 2, the OraQuick test performed on oral fluid
specimens had a sensitivity of 100% (95% CI 98, 100), and
specificity of 100% (95% CI 99, 100). Thus, the oral fluid test had
100% positive and negative predictive values. As shown in Table 3,
the OraQuick test performed on finger stick specimens had
a sensitivity of 100% (95% CI 98, 100), and a specificity of 99.7
(95% CI 98.4, 99.9). Agreement between the oral and finger stick
OraQuick test results was high (kappa=0.99; 95% CI 0.99, 1.00)).
Only one participant was found to be finger stick positive, but
oral test negative. In this participant, the reference standard tests
(ELISA/Western Blot) were negative on first time testing. On
retesting at 3 months, both OraQuick tests (i.e. finger stick and
oral) and the reference standard tests were negative. Thus, the
OraQuick finger stick test yielded one false positive result (false
positivity rate of 0.3%).
Client preference for various HIV testing modalities
Client preference was evaluated using face to face interviews, after
testing with oral, finger stick, and venipuncture specimens. When
participants were questioned about discomfort during collection of
each specimen, a majority (92%) reported no discomfort with
Oraquick oral test, followed by 75% for venipuncture-based blood
test and lastly, 66% for Oraquick finger stick tests. Discomfort was
most often reported with finger stick rapid test method. Further,
pain and fear of blood draw during finger stick sample collection
was reported by 24% of participants. Participants were questioned
after HIV testing regarding test preference. A majority (87%)
preferred the oral fluid OraQuick test for first time HIV testing
and for re-testing, a majority (60%) chose the OraQuick oral test.
DISCUSSION
In this study, the first field evaluation of the new and improved
OraQuickH rapid HIV-1/2 oral fluid test in rural India, we found
that the oral mucosal fluid test was 100% accurate. Accuracy of
the finger stick OraQuick test was comparable, although the finger
stick test yielded one false positive result (i.e. false positivity rate of
0.3%). A parallel testing strategy reduced the number of false
positives. Overall, the concordance between oral fluid and finger
stick testing was exceedingly high (kappa 0.99). The oral
OraQuick test yielded no false positive results, and all quality
assurance procedures were in place during the study period.
Apart from high accuracy, a key finding of our study was the
high level of client preference (87%) for the oral fluid-based
OraQuick test for initial testing, and 60% for re-testing. Preference
for oral HIV tests in previous studies ranged from 33% to 65%.
[10,11,12] There may be several reasons why our participants
preferred the oral fluid-based test: less discomfort, less pain,
greater cultural acceptability of giving oral fluid than blood speci-
mens, and novelty of the test. Our data suggest the potential use of
OraQuick oral fluid test for scale-up of HIV testing in rural India.
About one-third of the study participants tested positive
(seropositivity of 32% (95% CI 28%–37%). These estimates are
higher than a previous study in STD clinic attendees, conducted at
an urban hospital in India that reported 22% HIV seropositiv-
ity.[13] Our study was conducted in a select clinic population in
whom testing was indicated using a convenience-based sample.
Our study was not designed to estimate the prevalence of HIV
infection in the rural population.
How do our data on accuracy compare with previous studies?
This is the first report from rural India on high accuracy of the
new and improved oral OraQuick rapid HIV1/2 test compared to
the finger stick whole blood test. According to the OraSure
Technologies (PA, USA), the OraQuick test has a sensitivity of
100% and a specificity of 99.87%. OraQuick tests evaluated in
other settings (i.e., labor and delivery settings, emergency
departments and correctional facilities) showed sensitivity of
99.3% (95% CI 98.4, 99.7) and specificity of 99.8% (95% CI
99.6, 99.9) for oral fluid-based OraQuick, and sensitivity of 99.6%
(95% CI 98.5, 99.9), and specificity of 100% (95% CI 99.7, 100)
for whole blood-based OraQuick tests. [1–3,11,14–17]
Table 2. Diagnostic accuracy of the OraQuick HIV-1/2 rapid
test performed on oral mucosal fluid specimens
......................................................................
ELISA+Western
Blot positive
ELISA+Western
Blot negative Total
Oral fluid test positive 146 0 146
Oral fluid test negative 0 304 304
146 304 450
Sensitivity=100% (95% CI 98, 100)
Specificity=100% (95% CI 99, 100)
Positive predictive value=100%
Negative predictive value=100%
Positive likelihood ratio=NA
Negative likelihood ratio=0
doi:10.1371/journal.pone.0000367.t002
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Table 3. Diagnostic accuracy of the OraQuick HIV-1/2 rapid
test performed on finger stick blood specimens
......................................................................
ELISA+Western
Blot positive
ELISA+Western
Blot negative Total
Finger stick test positive 146 1 147
Finger stick test negative 0 303 304
146 304 450
Sensitivity=100% (95% CI 98, 100)
Specificity=99.7% (95% CI 98.4, 99.9)
Positive predictive value=98.17%
Negative predictive value=100%
Positive likelihood ratio=304
Negative likelihood ratio=0
doi:10.1371/journal.pone.0000367.t003
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study from India in pregnant women that reported a lower
sensitivity for the OraQuick salivary test.[14] Factors that could
partially explain the lower accuracy reported by the previous study
are: a) use of an earlier version of the OraQuick test, b) use of
a single ELISA test of lower diagnostic accuracy as the reference
standard. [14]
To summarize, the highly accurate OraQuick oral fluid-based
test was preferred by our participants for first time and second
time testing over conventional tests. Oral OraQuick test was 100%
accurate and performed marginally better than the finger stick
OraQuick test. Although one false-positive result was obtained
using the finger stick OraQuick test, the overall rate of false-
positive OraQuick results was very low, and therefore not
consistent with the recent reports from the United States.
Furthermore, the OraQuick tests were rapid, easy, feasible, and
convenient even in a rural hospital setting in India. These
characteristics have the potential to encourage people to present
for voluntary HIV testing. Oral fluid-based HIV testing in
outreach settings can help expand the existing voluntary testing
and counseling program in high prevalence countries such as
India. Our study suggests that oral OraQuick test could be used in
community-based surveys to estimate the true burden of HIV
infection in the country. In the context of global efforts to scale-up
HIV testing, our data suggests that oral fluid-based rapid HIV
testing may work well in rural resource limited settings, and greatly
enhance the control of the HIV epidemic in poor countries. In the
view of the high accuracy, feasibility and client preference, it is
important to ensure that oral fluid-based rapid tests are made
affordable in resource limited countries which need them the most.
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